TLDR Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
The study analyzed 855 severe alopecia areata (AA) patients from two phase III trials, BRAVE-AA1 and BRAVE-AA2, who were treated with either 4mg or 2mg of baricitinib. Patients were categorized into early, gradual, and late responders based on when they first achieved ≥ 30% improvement from baseline in Severity of Alopecia Tool (SALT) score. Among patients treated with 4mg baricitinib, 33% were early responders, 28% were gradual, and 8% were late. For those treated with 2mg, the proportions were 20%, 23%, and 9% respectively. Early responders had a shorter trajectory to maximal clinical outcomes. Responders were more frequent in patients with short (< 4 years) episodes of hair loss. The study concluded that these subgroups are influenced by baseline characteristics and will help inform treatment expectations for scalp hair regrowth.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
148 citations,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
53 citations,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
102 citations,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Restoring hair bulb immune privilege is crucial for managing alopecia areata.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
701 citations,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
148 citations,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
4 citations,
November 2018 in “JAAD case reports” Alopecia areata can sometimes appear as a straight line of hair loss instead of round patches.
May 2018 in “Journal of cosmetology & trichology” Combining platelet-rich plasma therapy with prostaglandin-F eye drops can significantly regrow hair in alopecia universalis.
